2.09 USD
-0.03 (-1.42%)
VTAK gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 184 industry peers in the Health Care Equipment & Supplies industry. VTAK has a bad profitability rating. Also its financial health evaluation is rather negative. VTAK is valued quite expensive, but it does show an excellent growth.
1. Profitability
1.1 Basic Checks
- In the past year VTAK has reported negative net income.
- In the past year VTAK has reported a negative cash flow from operations.
- VTAK had negative earnings in each of the past 5 years.
- In the past 5 years VTAK always reported negative operating cash flow.
1.2 Ratios
- With a Return On Assets value of -94.12%, VTAK is not doing good in the industry: 77.72% of the companies in the same industry are doing better.
- VTAK has a Return On Equity of -354.30%. This is in the lower half of the industry: VTAK underperforms 77.72% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -94.12% | ||
| ROE | -354.3% | ||
| ROIC | N/A |
ROA(3y)-156.76%
ROA(5y)-139.44%
ROE(3y)-270.77%
ROE(5y)-233.22%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- VTAK's Gross Margin of 92.33% is amongst the best of the industry. VTAK outperforms 98.37% of its industry peers.
- The Profit Margin and Operating Margin are not available for VTAK so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 92.33% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- VTAK does not have a ROIC to compare to the WACC, probably because it is not profitable.
- VTAK has more shares outstanding than it did 1 year ago.
- The debt/assets ratio for VTAK is higher compared to a year ago.
2.2 Solvency
- Based on the Altman-Z score of -18.07, we must say that VTAK is in the distress zone and has some risk of bankruptcy.
- VTAK's Altman-Z score of -18.07 is on the low side compared to the rest of the industry. VTAK is outperformed by 86.96% of its industry peers.
- VTAK has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
- The Debt to Equity ratio of VTAK (0.00) is better than 73.37% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -18.07 |
ROIC/WACCN/A
WACC9.41%
2.3 Liquidity
- VTAK has a Current Ratio of 0.44. This is a bad value and indicates that VTAK is not financially healthy enough and could expect problems in meeting its short term obligations.
- VTAK has a worse Current ratio (0.44) than 92.39% of its industry peers.
- VTAK has a Quick Ratio of 0.44. This is a bad value and indicates that VTAK is not financially healthy enough and could expect problems in meeting its short term obligations.
- Looking at the Quick ratio, with a value of 0.43, VTAK is doing worse than 92.39% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.44 | ||
| Quick Ratio | 0.43 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 70.00% over the past year.
- The Revenue has grown by 37.61% in the past year. This is a very strong growth!
- Measured over the past years, VTAK shows a very strong growth in Revenue. The Revenue has been growing by 167.26% on average per year.
EPS 1Y (TTM)70%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%93.12%
Revenue 1Y (TTM)37.61%
Revenue growth 3Y167.27%
Revenue growth 5YN/A
Sales Q2Q%127.96%
3.2 Future
- Based on estimates for the next years, VTAK will show a very strong growth in Earnings Per Share. The EPS will grow by 40.75% on average per year.
- The Revenue is expected to grow by 312.31% on average over the next years. This is a very strong growth
EPS Next Y96.27%
EPS Next 2Y40.75%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year533.33%
Revenue Next 2Y312.31%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for VTAK. In the last year negative earnings were reported.
- Also next year VTAK is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- VTAK's earnings are expected to grow with 40.75% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.75%
EPS Next 3YN/A
5. Dividend
5.1 Amount
- VTAK does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
CATHETER PRECISION INC / VTAK FAQ
What is the ChartMill fundamental rating of CATHETER PRECISION INC (VTAK) stock?
ChartMill assigns a fundamental rating of 2 / 10 to VTAK.
What is the valuation status for VTAK stock?
ChartMill assigns a valuation rating of 1 / 10 to CATHETER PRECISION INC (VTAK). This can be considered as Overvalued.
Can you provide the profitability details for CATHETER PRECISION INC?
CATHETER PRECISION INC (VTAK) has a profitability rating of 1 / 10.
What is the financial health of CATHETER PRECISION INC (VTAK) stock?
The financial health rating of CATHETER PRECISION INC (VTAK) is 1 / 10.
Can you provide the expected EPS growth for VTAK stock?
The Earnings per Share (EPS) of CATHETER PRECISION INC (VTAK) is expected to grow by 96.27% in the next year.